Peer-reviewed veterinary case report
Chewable amlodipine lowers high blood pressure in older cats
By Huhtinen, M et al.Ā·Published in Journal of veterinary internal medicineĀ·2015Ā·Orion Corporation Orion PharmaĀ·View original on PubMed ā
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research ā every detail traces back to the citation above. How we work ā
Original publication title: Randomized placebo-controlled clinical trial of a chewable formulation of amlodipine for the treatment of hypertension in client-owned cats.
- Species:
- cat
Plain-English summary
A 14-year-old cat with high blood pressure was treated with a new chewable form of amlodipine, a medication designed to lower blood pressure. After 28 days, the cats receiving amlodipine showed a significant drop in their blood pressure, with 63% of them responding positively to the treatment compared to only 18% in the placebo group. The cats tolerated the chewable tablets well, and they can also be safely used alongside other medications for cats with kidney issues. This new formulation could be a helpful option for managing hypertension in cats.
People also search for: cat high blood pressure treatment Ā· chewable amlodipine for cats Ā· cat hypertension medication
Abstract
BACKGROUND: There is an unmet clinical need for a cat-specific formulation of amlodipine to treat hypertensive cats. OBJECTIVES: To assess the efficacy of chewable amlodipine tablets in reducing systolic blood pressure (SBP) in cats diagnosed with systemic arterial hypertension. ANIMALS: Seventy-seven client-owned cats with systemic hypertension were included (median age 14 years). METHODS: The study was randomized, double-blinded, and placebo-controlled. Forty-two cats received 0.125-0.50 mg/kg amlodipine once daily for 28 days; 35 cats received placebo. After 28 days all cats continued with amlodipine for 2-3 months in an open-label phase. Blood pressure was measured using high definition oscillometry. A responder was defined as a cat showing a decrease of SBP to <150 mmHg at 28 days or a decrease from baseline ≥15%. RESULTS: Sixty-one cats completed the study. The responder rate was 63% in amlodipine group and 18% in placebo group. Cats receiving amlodipine were 7.9 (95% CI 2.6-24.1) times more likely to be classified as responders when compared to those receiving placebo (P < .001). From a mean (±SD) baseline value of 181 (±12) mmHg, SBP decreased to 154 (±17) mmHg with amlodipine and to 170 (±21) mmHg with placebo (P < .001). The voluntary acceptance rate of amlodipine formulation was 73%. CONCLUSIONS AND CLINICAL IMPORTANCE: The chewable amlodipine tablet effectively reduced SBP compared with placebo in hypertensive cats, and was well-tolerated. It can be used concomitantly with angiotensin-converting enzyme inhibitors and in cats with chronic kidney disease.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases āOriginal publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/25857394/